Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction

Clinical Chemistry

Volumn 58, Issue 7, 2012, Pages 1110-1115

  Xu, Shengyuan ^a   Lind, Lars ^a   Zhao, Linshu ^a,b   Lindahl, Bertil ^a,c   Venge, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Uppsala Research Center   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; PROLINE CARBOXYPEPTIDASE;

AGED; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PURIFICATION; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NERVE CELL NETWORK; NEUTROPHIL; OBESITY; PLASMA; SENSITIVITY ANALYSIS; THORAX PAIN;

AGED; CARBOXYPEPTIDASES; CARDIOVASCULAR DISEASES; CHEST PAIN; COHORT STUDIES; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MYOCARDIUM; OBESITY; PLAQUE, ATHEROSCLEROTIC;

ANIMALIA;

EID: 84863591115     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.179291     Document Type: Article

References (22)

1. Mallela J, Yang J, Shariat-Madar Z. Prolylcarboxypeptidase: a cardioprotective enzyme. Int J Biochem Cell Biol 2009;41:477-81.
2. Shariat-Madar B, Kolte D, Verlangieri A, Shariat-Madar Z. Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment. Diabetes Metab Syndr Obes 2010;3:67-78.
3. Watson B Jr, Nowak NJ, Myracle AD, Shows TB, Warnock DG. The human angiotensinase C gene (HUMPCP) maps to 11q14 within 700 kb of D11S901: a candidate gene for essential hypertension. Genomics 1997;44:365-7. (Pubitemid 27419016)
4. Moreira CR, Schmaier AH, Mahdi F, da Motta G, Nader HB, Shariat-Madar Z. Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett 2002;523:167-70. (Pubitemid 34786080)
5. Odya CE, Erdos EG. Human prolylcarboxypeptidase. Methods Enzymol 1981;80(Pt C):460-6.
6. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdos EG. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 1978;253:5927-31. (Pubitemid 9014225)
7. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002;277:17962-9. (Pubitemid 34967607)
8. Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E, Liu ZW, et al. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest 2009;119:2291-303.
9. Zhou C, Garcia-Calvo M, Pinto S, Lombardo M, Feng Z, Bender K, et al. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity. J Med Chem 2010;53:7251-63.
10. Eggers KM, Ellenius J, Dellborg M, Groth T, Oldgren J, Swahn E, Lindahl B. Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients. Int J Cardiol 2007;114:366-74. (Pubitemid 44855917)
11. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005;25:2368-75. (Pubitemid 41552656)
12. Andersson J, Sundstrom J, Kurland L, Gustavsson T, Hulthe J, Elmgren A, et al. The carotid artery plaque size and echogenicity are related to different cardiovascular risk factors in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Lipids 2009;44:397-403.
13. Lind L. Arterial compliance and endothelium-dependent vasodilation are independently related to coronary risk in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Clin Physiol Funct Imaging 2008;28:373-7.
14. Lind L, Andersson J, Ronn M, Gustavsson T, Holdfelt P, Hulthe J, et al. Brachial artery intima-media thickness and echogenicity in relation to lipids and markers of oxidative stress in elderly subjects:-the prospective investigation of the vasculature in Uppsala Seniors (PIVUS) Study. Lipids 2008;43:133-41.
15. Sorrells K, Erdos EG. Prolylcarboxypeptidase in biological fluids. Adv Exp Med Biol 1971;23:393-7.
16. Kumamoto K, Stewart TA, Johnson AR, Erdos EG. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J Clin Invest 1981;67:210-5. (Pubitemid 11163174)
17. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009;30:2346-53.
18. Tan F, Morris PW, Skidgel RA, Erdos EG. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem 1993;268:16631-8. (Pubitemid 23229975)
19. Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C, Yang XP. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 2010;56:384-90.
20. McCarthy JJ, Meyer J, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet 2003;114:87-98. (Pubitemid 38165539)
21. Chen WC, Tran KD, Maisel AS. Biomarkers in heart failure. Heart 2010;96:314-20.
22. Adams GN, Larusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 2011;117:3929-37.